This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 Apr;12(4):256-7.

doi: 10.1016/S1473-3099(12)70013-0. Epub 2012 Feb 8.

Progress with a difficult infection

Mark H Wilcox¹

Affiliations

PMID: 22321771
DOI: 10.1016/S1473-3099(12)70013-0

Comment

Progress with a difficult infection

Mark H Wilcox. Lancet Infect Dis. 2012 Apr.

. 2012 Apr;12(4):256-7.

doi: 10.1016/S1473-3099(12)70013-0. Epub 2012 Feb 8.

Author

Mark H Wilcox¹

Affiliation

¹ Microbiology Department, Old Medical School, Leeds General Infirmary and University of Leeds, Leeds LS1 3EX, UK. mark.wilcox@leedsth.nhs.uk

PMID: 22321771
DOI: 10.1016/S1473-3099(12)70013-0

No abstract available

PubMed Disclaimer

Comment on

Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S; OPT-80-004 Clinical Study Group. Cornely OA, et al. Lancet Infect Dis. 2012 Apr;12(4):281-9. doi: 10.1016/S1473-3099(11)70374-7. Epub 2012 Feb 8. Lancet Infect Dis. 2012. PMID: 22321770 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information